Nasséra Chalabi

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2014 · 122 citations

Breast Oncology, Medicine, Treatment Impact +8

Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by Polymerase Chain Reaction arrays in human prostate cancer cell lines

Nadège Rabiau, Myriam Kossaï, Martin Braud et al. · Cancer Epidemiology · 2010 · 73 citations

Polymerase Chain Reaction, Oncogenic Agent, Cell Cycle +6

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Alwin Krämer, Tilmann Bochtler, Chantal Pauli et al. · The Lancet · 2024 · 58 citations · Full text

Therapy Versus Chemotherapy, Health Sciences, Medicine +11

The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression

Nasséra Chalabi, Ludovic Le Corre, Maurizis Jc et al. · European Journal of Cancer · 2004 · 57 citations

Tumor Biology, Brca2 Gene Expression, Breast Oncology +10

Gene Signature of Breast Cancer Cell Lines Treated with Lycopene

Nasséra Chalabi, Laëtitia Delort, Ludovic Le Corre et al. · Pharmacogenomics · 2006 · 57 citations